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Fig. 1. Liver biopsies demonstrating typical features of AIH. Liver biopsy from
the ﬁrst patient, after four months treatment with adalimumab, shows expansion
of portal areas due to predominant plasma cell inﬁltrate with prominent interface
inﬂammatory activity and bridging necrosis (A and B). Liver biopsy from the
second patient, after twelve months treatment with inﬂiximab, shows massive
hepatic necrosis with almost complete destruction of hepatocytes within the
sampled tissue, portal triad expansion with connective tissue, bile duct prolif-
eration and predominant lymphoplasmacytic cell inﬁltrate (C and D). (This ﬁgure
appears in colour on the web.)We read with interest the report by Weiler-Normann et al. [1]
evaluating the safety and efﬁcacy of inﬂiximab as a rescue ther-
apy in difﬁcult-to-treat autoimmune hepatitis (AIH). TNF-tar-
geted therapies are widely used for treating a rapidly growing
number of autoimmune diseases. However despite their effec-
tiveness in many of these diseases, there have been increasing
reports of autoimmune processes developing de novo after their
use, including AIH. This is highlighted by our experience with
two cases of severe anti-TNF therapy-induced AIH.
The ﬁrst patient, a 60-year-old woman with a 20-year history
of rheumatoid arthritis, treated with prednisone 5 mg/day, with
remote exposure to methotrexate (MTX). She presented with ele-
vated liver enzymes four months after treatment with ada-
limumab, which had been normal prior to anti-TNF therapy.
Her liver enzymes were grossly abnormal with ALT 923 IU/L (nor-
mal <40 IU/L), AST 1146 IU/L (normal <32 IU/L), bilirubin
76 lmol/L (normal <20 lmol/L), INR 1.1 (normal 0.9–1.1), and
albumin 36 g/L (normal 33–48 g/L). Anti-nuclear antibody
(ANA) was positive, documented prior to initiation of anti-TNF
therapy, anti-smooth muscle antibody (ASMA) negative, and
IgG level normal at 15.52 g/L (normal 6.80–18.00 g/L). ds-DNA
antibodies were highly positive. Despite discontinuing ada-
limumab, over the following month she developed features of
progressive liver failure with INR 1.8, albumin 16 g/L, bilirubin
271 lmol/L, pruritis, and progressive lower extremity edema.
There was no hepatic encephalopathy. Fibroscan showed a liver
stiffness of 33.3 kPa (IQR 4.8 kPa; 100% success). Liver biopsy
showed features consistent with AIH, including expansion of por-
tal areas with dense plasma cell inﬁltrates, prominent interface
activity, and bridging necrosis (Fig. 1A and B). Prednisone
40 mg/day was started in combination with azathioprine
50 mg/day. Liver enzymes completely normalized within 8 weeks
of treatment. Serial ﬁbroscans showed a striking improvement in
liver stiffness, with her most recent liver stiffness measure of
5.4 kPa (IQR 0.9 kPa; 77% success). She remains in biochemical
remission and is currently being reconsidered for alternative
anti-TNF therapy for management of her rheumatoid arthritis.
The second patient is a 48-year-old woman with an 18 year
history of rheumatoid arthritis. She was treated with MTX and
naproxen, both of which were discontinued in November 2010
due to elevated ALT (158 IU/L). Liver enzymes completely nor-
malized following drug withdrawal (ALT 19 IU/L; June 2011). In
July 2011 she was started on inﬂiximab (IFX) 5 mg/kg and after
12 months of therapy she was admitted to hospital with hepatic
failure with INR 1.6, albumin 22 g/L, bilirubin 408 lmol/L, ALT
505 IU/L, AST 1614 IU/L, and moderate ascites. She had no hepatic
encephalopathy. ANA was positive (negative prior to treatment
with IFX), ASMA negative, and IgG level elevated at 27.8 g/L. Liver
biopsy showed features consistent with severe AIH including
submassive hepatic necrosis with plasma cell rich inﬂammation
and signiﬁcant ﬁbrosis (Fig. 1C and D). Fibroscan revealed a liver
stiffness of 24.6 kPa (IQR 14.4; 63% success). IFX wasJournal of Hepatology 2
license.discontinued and prednisone started at 50 mg/day in combina-
tion with azathioprine 50 mg/day. Biochemical remission
occurred after 8 weeks of treatment. Repeat Fibroscan after
14 months of treatment showed a marked improvement in liver
stiffness (6.2 kPa; IQR 1.4; 100% success). She was recently
started on tocilizumab (IL-6 receptor antagonist) with close mon-
itoring of liver enzymes.
Biological agents are increasingly used in the treatment of
autoimmune diseases, however a growing number of reports
have outlined the paradoxical induction of autoimmune pro-
cesses. To date there have been roughly 20 cases of drug-induced
autoimmune liver injury reported with anti-TNF therapy [2], with
the majority of cases occurring between one month to one year
after initiation of anti-TNF therapy [3]. Anti-TNF-induced AIH
has occurred most commonly with IFX and much less commonly
with adalimumab or etanercept [4]. Most patients respond com-
pletely to anti-TNF withdrawal and treatment with corticoste-
roids, with a few cases of spontaneous recovery with drug
withdrawal alone [4]. Overall prognosis is favorable, and normal-
ization of liver enzymes generally rapid. There is however a sin-
gle report of a patient requiring liver transplantation after
developing severe cholestatic hepatitis related to IFX [5]. Treat-
ment with an alternative TNF antagonist after resolution of the
liver injury appears to be generally well tolerated, without recur-014 vol. 61 j 169–182
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rence [4,6–8]. Whether anti-TNF-induced liver damage reﬂects
drug-induced immune-mediated liver injury, or induction of de
novo autoimmune hepatitis remains controversial [9]. Typically,
liver biopsies from these patients exhibit many of the classical
features of AIH, and immunosuppressive therapy is typically
required for resolution of liver inﬂammation [4–8]. However,
the lack of chronicity or disease relapse on withdrawal of immu-
nosuppression favors drug-induced immune-mediated liver
injury.
Although anti-TNF-induced AIH is uncommon, it is being
increasingly described. We report two cases of severe AIH associ-
ated with anti-TNF therapy. In both cases, the patients responded
to withdrawal of anti-TNF therapy and immunosuppressive treat-
ment. Our cases and other reports of anti-TNF-induced AIH, cou-
pled with the recent report by Weiler-Normann et al. [1],
highlight important paradoxical clinical effects of anti-TNF ther-
apy; having the capacity to both ameliorate and induce AIH. A
number of studies have deﬁned both pro-inﬂammatory and
anti-inﬂammatory effects of TNF, mainly through the differential
activation of the two TNF receptors (TNFR1 and TNFR2) expressed
on T cells [10]. Speciﬁcally, TNF can activate effector T cell func-
tion, mainly through TNFR1, which drives inﬂammatory
responses [10,11]. In contrast, TNF stimulation of TNFR2
expressed on regulatory T cells expands the highly suppressive
pool of these cells, which in turn prevents autoimmunity and
attenuates inﬂammation [11]. Therefore, anti-TNF therapy may
either induce or suppress autoimmune inﬂammatory responses
by altering the balance between effector and regulatory T cell
activation [11]. In addition, differential hepatic immune
responses to anti-TNF therapy may also be inﬂuenced by host
genetics and the hepatic microenvironment (e.g., cytokine milieu,
TNFR expression proﬁle, cellular sources of TNF). These potential
explanations for the opposing effects of anti-TNF therapy in
liver autoimmunity should be examined in future studies in this
ﬁeld.
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To the Editor:
We would like to thank Dr. Borman [1] and colleagues for their
case presentations illustrating the potentially harmful impact of
anti-TNF-agents on the liver: In this case in their ability to induce
autoimmune hepatitis (AIH). We have previously shown that
inﬂiximab, one of the anti-TNF-drugs, may successfully treat
AIH in selected difﬁcult-to-treat cases [2].
It is well known, that autoimmune features may occur dur-
ing treatment with anti-TNF-agents, especially the emergence
of anti-dsDNA-antibodies has been described in up to 30% of
the patients [3]. Yet, not all patients who develop autoantibod-
ies will also develop clinical symptoms or disease. Further on,
most patients at risk are likely to have a strong genetic back-
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ground for the development of autoimmune diseases as anti-
TNF-agents are primarily used to treat autoimmune diseases.
Therefore, it seems necessary to discriminate between de novo
autoimmune diseases in genetically prone patients and paradox-
ical inﬂammation that may also develop as a consequence of
use of these agents. Especially for inﬂiximab, the oldest among
the recombinant antibodies (and unlike etanercept as a soluble
receptor also binding to cell-bound TNF), a wide number of
immunological side effects have been described [4], among oth-
ers psoriasis-like lesions, lupus like syndrome, systemic lupus
erythematodes, (paradoxical) joint inﬂammation, (de-novo)
inﬂammatory bowel disease, uveitis as well as different forms
of vasculitis [5].
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